BDRX
Income statement / Annual
Last year (2023), Biodexa Pharmaceuticals Plc's total revenue was $381,000.00,
a decrease of 45.49% from the previous year.
In 2023, Biodexa Pharmaceuticals Plc's net income was -$7.08 M.
See Biodexa Pharmaceuticals Plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$381,000.00
|
$699,000.00
|
$578,000.00
|
$343,000.00
|
$674,000.00
|
$1.94 M
|
$989,000.00
|
$1.32 M
|
$1.38 M
|
$157,000.00
|
| Cost of Revenue |
$4.07 M |
$5.11 M |
$4.65 M |
$6.07 M |
$7.84 M |
$9.36 M |
$8.33 M |
$7.73 M |
$70,000.00 |
$0.00 |
| Gross Profit |
-$3.69 M |
-$4.41 M |
-$4.08 M |
-$5.73 M |
-$7.17 M |
-$7.42 M |
-$7.34 M |
-$6.41 M |
$1.31 M |
$157,000.00 |
| Gross Profit Ratio |
-9.67 |
-6.31 |
-7.05 |
-16.69 |
-10.64 |
-3.83 |
-7.42 |
-4.84 |
0.95 |
1 |
| Research and Development
Expenses |
$4.07 M
|
$5.11 M
|
$4.65 M
|
$16.15 M
|
$7.84 M
|
$9.36 M
|
$9.83 M
|
$7.73 M
|
$8.71 M
|
$5.44 M
|
| General & Administrative
Expenses |
$4.34 M
|
$4.54 M
|
$2.95 M
|
$4.96 M
|
$3.84 M
|
$4.39 M
|
$4.27 M
|
$3.25 M
|
$2.08 M
|
$4.23 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$6,000.00
|
$323,000.00
|
$0.00
|
$170,000.00
|
$0.00
|
$605,000.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$4.34 M
|
$4.54 M
|
$2.95 M
|
$4.96 M
|
$4.16 M
|
$4.39 M
|
$4.44 M
|
$3.25 M
|
$2.69 M
|
$4.23 M
|
| Other Expenses |
-$4.08 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$4.33 M |
$4.05 M |
$1.99 M |
$17.71 M |
$3.67 M |
$4.39 M |
$5.54 M |
$2.07 M |
$12.59 M |
$9.84 M |
| Cost And Expenses |
$8.40 M |
$9.16 M |
$6.64 M |
$23.78 M |
$11.51 M |
$13.75 M |
$13.87 M |
$9.80 M |
$12.66 M |
$9.84 M |
| Interest Income |
$83,000.00 |
$24,000.00 |
$44,000.00 |
$33,000.00 |
$89,000.00 |
$585,000.00 |
$94,000.00 |
$91,000.00 |
$48,000.00 |
$153,000.00 |
| Interest Expense |
$41,000.00 |
$53,000.00 |
$44,000.00 |
$34,000.00 |
$97,000.00 |
$587,000.00 |
$109,000.00 |
$0.00 |
$0.00 |
$161,000.00 |
| Depreciation &
Amortization |
$283,000.00
|
$343,000.00
|
$403,000.00
|
$1.22 M
|
$1.29 M
|
$1.11 M
|
$1.17 M
|
$4.35 M
|
$736,000.00
|
$321,000.00
|
| EBITDA |
-$7.16 M
|
-$7.40 M
|
-$5.66 M
|
-$22.22 M
|
-$9.54 M
|
-$10.70 M
|
-$10.61 M
|
-$5.30 M
|
-$10.49 M
|
-$9.36 M
|
| EBITDA Ratio |
-18.8 |
-12.53 |
-11.74 |
-27.91 |
-15.34 |
-5.52 |
-10.73 |
-4.01 |
-6.8 |
-47.1 |
| Operating Income Ratio
|
-21.03
|
-12.78
|
-12.11
|
-31.11
|
-16.79
|
-6.1
|
-11.91
|
-7.3
|
-7.34
|
-49.14
|
| Total Other
Income/Expenses Net |
$529,000.00
|
$444,000.00
|
$892,000.00
|
-$430,000.00
|
$395,000.00
|
-$585,000.00
|
-$1.19 M
|
$1.26 M
|
$1.69 M
|
-$153,000.00
|
| Income Before Tax |
-$7.49 M |
-$8.49 M |
-$6.11 M |
-$23.47 M |
-$10.92 M |
-$12.40 M |
-$12.97 M |
-$8.39 M |
-$11.23 M |
-$9.84 M |
| Income Before Tax Ratio
|
-19.65
|
-12.14
|
-10.56
|
-68.43
|
-16.21
|
-6.4
|
-13.11
|
-6.34
|
-8.17
|
-62.68
|
| Income Tax Expense |
-$406,000.00 |
$832,000.00 |
$646,000.00 |
$1.28 M |
$1.79 M |
$2.03 M |
$1.27 M |
$2.23 M |
$1.13 M |
$1.02 M |
| Net Income |
-$7.08 M |
-$7.66 M |
-$5.46 M |
-$22.19 M |
-$9.14 M |
-$10.37 M |
-$11.71 M |
-$6.16 M |
-$10.10 M |
-$8.82 M |
| Net Income Ratio |
-18.58 |
-10.95 |
-9.45 |
-64.69 |
-13.56 |
-5.35 |
-11.84 |
-4.66 |
-7.34 |
-56.19 |
| EPS |
-224.13 |
-619.72 |
-542.31 |
-4143.6 |
-3988.65 |
0 |
0 |
0 |
0 |
0 |
| EPS Diluted |
-224.13 |
-619.72 |
-542.31 |
-4143.6 |
-3988.65 |
0 |
0 |
0 |
0 |
0 |
| Weighted Average Shares
Out |
$31,585.00
|
$12,354.00
|
$10,068.00
|
$5,355.00
|
$2,291.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$31,585.00
|
$12,354.00
|
$10,068.00
|
$5,355.00
|
$2,291.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
